Sphingosine 1-phosphate as a therapeutic target in heart failure: More questions than answers

Circulation

Volumn 125, Issue 22, 2012, Pages 2692-2694

  Mann, Douglas L ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Editorials; Genes; Heart failure; Sphingosine 1 phosphate; Therapeutic target; Vascular response

Indexed keywords

2 AMINO 2 (3 OCTYLPHENYLCARBAMOYL)ETHYL PHOSPHATE; 2 AMINO 2 [2 [4 (3 BENZYLOXYPHENYLTHIO) 2 CHLOROPHENYL]ETHYL] 1,3 PROPANEDIOL; 3 [2 (3 TRIFLUOROMETHYL 4 BIPHENYLYL)BENZO[B]THIEN 5 YLMETHYLAMINO]PROPIONIC ACID; 5 (4 PHENYL 5 TRIFLUOROMETHYL 2 THIENYL) 3 (3 TRIFLUOROMETHYLPHENYL) 1,2,4 OXADIAZOLE; AAL R; ABC 294640; ACETYLCHOLINE; COMPOUND 5; CYM 5442; FINGOLIMOD; LX 2931; MESSENGER RNA; PHENYLEPHRINE; PONESIMOD; PROHIBITIN; PROTEIN KINASE C DELTA; SAFINGOL; SK 11; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE 1 PHOSPHATE RECEPTOR; TRANSMEMBRANE CONDUCTANCE REGULATOR; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2; TY 52156; UNCLASSIFIED DRUG; VPC 44116; W 146;

ALZHEIMER DISEASE; ARTERY LIGATION; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CELL PROLIFERATION; CELLULAR DISTRIBUTION; DIABETES MELLITUS; EDITORIAL; HEART ARRHYTHMIA; HEART FAILURE; HUMAN; IMMUNOREGULATION; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MULTIPLE SCLEROSIS; NONHUMAN; OSTEOPOROSIS; PERIPHERAL VASCULAR SYSTEM; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; TISSUE DISTRIBUTION; VASCULAR RESISTANCE; VASCULAR SMOOTH MUSCLE; VASOCONSTRICTION;

ANIMALS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DOWN-REGULATION; HEART FAILURE; LYSOPHOSPHOLIPIDS; SIGNAL TRANSDUCTION; SPHINGOSINE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84861872296     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.112.107797     Document Type: Editorial

References (19)

1. Means CK, Brown JH. Sphingosine-1-phosphate receptor signalling in the heart. Cardiovasc Res. 2009;82:193-200.
2. Boujaoude LC, Bradshaw-Wilder C, Mao C, Cohn J, Ogretmen B, Hannun YA, Obeid LM. Cystic fibrosis transmembrane regulator regulates uptake of sphingoid base phosphates and lysophosphatidic acid: modulation of cellular activity of sphingosine 1-phosphate. J Biol Chem. 2001;276:35258-35264.
3. Wang TJ, Larson MG, Benjamin EJ, Siwik DA, Safa R, Guo CY, Corey D, Sundstrom J, Sawyer DB, Colucci WS, Vasan RS. Clinical and echocardiographic correlates of plasma procollagen type III aminoterminal peptide levels in the community. Am Heart J. 2007;154: 291-297. (Pubitemid 47069123)
4. Torre-Amione G, Kapadia S, Benedict CR, Oral H, Young JB, Mann DL. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the studies of left ventricular dysfunction (SOLVD). J Am Coll Cardiol. 1996;27:1201-1206. (Pubitemid 26117714)
5. Kapadia S, Torre-Amione G, Yokoyama T, Mann DL. Soluble tumor necrosis factor binding proteins modulate the negative inotropic effects of TNF-a in vitro. Am J Physiol. 1995;37:H517-H525.
6. Means CK, Xiao CY, Li Z, Zhang T, Omens JH, Ishii I, Chun J, Brown JH. Sphingosine 1-phosphate S1P2 and S1P3 receptor-mediated Akt activation protects against in vivo myocardial ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol. 2007;292:H2944-H2951. (Pubitemid 47084545)
7. Camerer E, Regard JB, Cornelissen I, Srinivasan Y, Duong DN, Palmer D, Pham TH, Wong JS, Pappu R, Coughlin SR. Sphingosine-1-phosphate in the plasma compartment regulates basal and inflammation-induced vascular leak in mice. J Clin Invest. 2009;119:1871-1879.
8. Schuchardt M, Tolle M, Prufer J, van der Giet M. Pharmacological relevance and potential of sphingosine 1-phosphate in the vascular system. Br J Pharmacol. 2011;163:1140-1162.
9. Maceyka M, Harikumar KB, Milstien S, Spiegel S. Sphingosine-1-phosphate signaling and its role in disease. Trends Cell Biol. 2012;22: 50-60.
10. Pan S, Mi Y, Pally C, Beerli C, Chen A, Guerini D, Hinterding K, Nuesslein-Hildesheim B, Tuntland T, Lefebvre S, Liu Y, Gao W, Chu A, Brinkmann V, Bruns C, Streiff M, Cannet C, Cooke N, Gray N. A monoselective sphingosine-1-phosphate receptor-1 agonist prevents allograft rejection in a stringent rat heart transplantation model. Chem Biol. 2006;13:1227-1234. (Pubitemid 44762192)
11. Keul P, Tolle M, Lucke S, von Wnuck LK, Heusch G, Schuchardt M, van der Giet M, Levkau B. The sphingosine-1-phosphate analogue FTY720 reduces atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2007;27:607-613.
12. Egom EE, Ke Y, Musa H, Mohamed TM, Wang T, Cartwright E, Solaro RJ, Lei M. FTY720 prevents ischemia/reperfusion injury-associated arrhythmias in an ex vivo rat heart model via activation of Pak1/Akt signaling. J Mol Cell Cardiol. 2010;48:406-414.
13. Verkman AS, Galietta LJ. Chloride channels as drug targets. Nat Rev Drug Discov. 2009;8:153-171.
14. Koelling TM, Dec GW, Ginns LC, Semigran MJ. Left ventricular diastolic function in patients with advanced cystic fibrosis. Chest. 2003;123: 1488-1494. (Pubitemid 36549767)
15. Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, Drevinek P, Griese M, McKone EF, Wainwright CE, Konstan MW, Moss R, Ratjen F, Sermet-Gaudelus I, Rowe SM, Dong Q, Rodriguez S, Yen K, Ordonez C, Elborn JS. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med. 2011;365:1663-1672.
16. Meissner A, Yang J, Kroetsch JT, Sauve M, Dax H, Momen A, Noyen-Ashraf MH, Heximer S, Hussain M, Lidington D, Bolz SS. Tumor necrosis factor-mediated downregulation of the cystic fibrosis transmembrane conductance regulator drives pathological sphingosine-1-phosphate signaling in a mouse model of heart failure. Circulation. 2012;125:2739-2750.
17. Knapp M, Baranowski M, Lisowska A, Musial W. Decreased free sphingoid base concentration in the plasma of patients with chronic systolic heart failure. Adv Med Sci. 2012:1-6.
18. Pyne S, Pyne NJ. Translational aspects of sphingosine 1-phosphate biology. Trends Mol Med. 2011;17:463-472.
19. Edmonds Y, Milstien S, Spiegel S. Development of small-molecule inhibitors of sphingosine-1-phosphate signaling. Pharmacol Ther. 2011;132:352-360.